Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project.

ABSTRACT:

Introduction

Amidst growing consensus that stakeholder decision-making during drug development should be informed by an understanding of patient preferences, the Innovative Medicines Initiative project 'Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle' (PREFER) is developing evidence-based recommendations about how and when patient preferences should be integrated into the drug life cycle. This protocol describes a PREFER clinical case study which compares two preference elicitation methodologies across several populations and provides information about benefit-risk trade-offs by those at risk of rheumatoid arthritis (RA) for preventive interventions.

Methods and analysis

This mixed methods study will be conducted in three countries (UK, Germany, Ro

SUBMITTER: Falahee M 

PROVIDER: S-EPMC8039213 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature